Boehringer Ingelheim Pharmaceuticals, Inc. recalls JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) b
Recalled March 29, 2023 · FDA recall D-0468-2023 · Boehringer Ingelheim Pharmaceuticals
Hazard
Labeling: Label Mix-up · FDA Class II
Units
69,375 bottles
Sold at
Product was distributed nationwide within the United States and PR
Description
Labeling: Label Mix-up
Product
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Manufacturer(s)
Boehringer Ingelheim Pharmaceuticals, Inc.
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →